A prescription medication used in the treatment of diabetes as well as obesity has been hit with three separate product recalls.

The Ministry of Health announced that semaglutide injection products on the local market had been flagged up for “product impurities, incorrect dose display and packaging errors that may result in patients receiving the wrong dose”.

All the island’s pharmacies and medical warehouses were notified.

Semaglutide is used in adults to improve blood‑glucose control, with accurate dosing vital for safe treatment. Affected products were said to be:

• Novo Nordisk Canada Inc: incorrect pen in package for 4 mg/3ml semaglutide; DIN 02540258; lot LP1107; expiry August 31, 2026

• Dr Reddy’s Laboratories Canada Inc: impurity affecting 1.34 mg/ml semaglutide solution; DIN: 02567806, lots 7000544, 7000545, 7000546; DIN 02567814, lots 7000542, 7000543, 7000624, 7000628, 7000629; patients advised to verify whether their product is affected and consult healthcare provider before discontinuing use

• Apotex Inc: apo‑semaglutide incorrect dose display may show a 2 mg dose in the dose window and deliver a 2 mg dose instead of the expected 0.25 mg or 0.5 mg dose; affecting apo‑semaglutide 2 mg/pen; DIN 02568020; strength 0.68 mg/ml; lot 7000599A — risk of potential “significant under or overdosing for patients following titration schedules”.

Patients were advised not to use any affected product before verifying the lot number and confirming whether your supply is under recall, and to return affected products to the pharmacy where they were purchased for replacement, alternative supply and proper disposal.

Users should contact their healthcare provider before pausing treatment, or with any concerns about dosing or adverse effects.

Anyone unsure whether their medication is affected should contact your pharmacy directly.

Patients who received semaglutide dispensed into vials or alternative packaging should note that the pharmacy’s name will be printed on the label, and should contact that pharmacy to confirm whether their supply is affected.

Kim Wilson, the Minister of Health, said: “While these recalls stem from manufacturer quality and packaging issues, we are acting quickly to make sure patients and healthcare providers have clear information.”

The ministry said it was monitoring the situation and would share updates promptly.